News

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Initial consultations by female gastroenterologists led to a significant reduction in subsequent healthcare utilization compared with male gastroenterologists.

Jared Hassler, MD, shares his personal journey with IgAN and discusses IgAN's clinical features and diagnosis, emphasizing the importance of routine screenings for early detection.

The smartphone app demonstrated higher accuracy, sensitivity, and specificity in patients with severe anemia than those with moderate anemia.

This analysis may help bring to light more specific skin cancer-related data on the underserved population of non-Hispanic Black, or NHB, patients.

Patients with IgAN receiving iptacopan achieved a 38.3% reduction in proteinuria at month 9.

HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings.

This analysis highlights the various factors influencing preferences in skin cancer detection between smartphone applications using artificial intelligence versus dermatologists.

Patients who missed their initial HCV treatment appointment had greater housing instability, transportation difficulty, and a history of medication non-adherence.

Kam Kalantar-Zadeh, MD, MPH, PhD, discusses his presentation focusing on dietary challenges, potassium control, and potential solutions associated with RAASi therapy.

Kam Kalantar-Zadeh, MD, MPH, PhD, addresses the challenge healthcare providers encounter in balancing the cardiovascular advantages of RAASi therapy with the potential hazards of hyperkalemia.

From the prospect of semaglutide and MDMA for substance use disorder to evolving research around personality disorders and OCD, here are 5 key topics from the annual psychiatric meeting.

These data highlight the effects of psoriasis on the mental health of adolescents in Denmark.

An analysis of FDA Adverse Event Reporting System data suggests baloxavir marboxil has lower hepatic toxicity than oseltamivir and may be a safer option for patients with liver diseases.

Maya N. Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for micronutrient supplementation!

The announcement from Bristol Myers Squibb indicates deucravacitinib led to significant improvements in patients’ PASI and sPGA scores after 4 years of treatment.

In this analysis of independent risk factors for developing PsA from psoriasis, the use of MRI to detect such factors was noted as helpful for investigators.

Liposomal iron achieves a partial correction of transferrin saturation, with no significant effect on iron storage and hemoglobin, in patients with NDD-CKD.

Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.

Results of the single-center study showed HCV treatment from PCPs decreased from 2015-2022 but must be improved to help reach elimination goals.

Areef Ishani, MD, MS, discusses the results of the Diuretic Comparison Project (DCP), which compared chlorthalidone and hydrochlorothiazide for the treatment of cardiovascular diseases.

Automated anemia detection from fundus images may benefit patients undergoing routine retinal imaging.

New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.

These data highlighted patient-reported and clinical outcomes among those with psoriasis, with data drawn retrospectively from Germany, Poland, Czech Republic, Japan, and Canada.

Study results showed systemic corticosteroids induced greater remission rates alone than in combination with other immunosuppressive treatments but were linked to adverse events.